Venom poisons from the Egyptian cobra Naja haje: Possible treatments for Breast cancer | ||||
| Bulletin of Faculty of Science, Zagazig University | ||||
| Article 9, Volume 2025, Issue 3, July 2025, Page 105-111 PDF (996.15 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfszu.2024.341827.1452 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hebat alah Ali1; Nabil Soliman  1; Amr A. Shalaby2
| ||||
| 1Physiology departement Faculty of science Zagazig university Egypt | ||||
| 2Physiology departement | ||||
| Abstract | ||||
| The majority of cobra species are categorised as Category 1 by the WHO. Cobras are members of the Elapidae family of snakes, represented by the genus Naja (nāgá, which means "snake" in Sanskrit).In addition to discussing the effectiveness of current antivenoms in reducing the toxic effects, From the standpoint of histopathological impacts on breast cancer. The poison found in snake venom is a mixture of substances, with proteins and peptides predominating. Snake venom's toxic components target the kidney, blood coagulation system, neuromuscular system, and other parts of the human body, causing diseases. Therefore, it is possible to control and treat these illnesses with venom toxins. . The study investigates the anticancer effect of Egyptian cobra Naja haje venom alone and in combination with Nanoparticles on Triple-negative breast cancer (TNBC) in vivo. The study involved dividing experimental animals into five groups, each with 10 rats, each treated with different doses of crude venom, G2 and G3, respectively. The study involved loading venom onto nanoparticle-based delivery systems, measuring histopathological examination of breast tissue. The study involved administering Naja haje crude venom at higher (1/5 LD50) and lower (1/20 LD50) dose levels in groups G2 and G3, respectively | ||||
| Keywords | ||||
| Cobra venom; anti-tumour; apoptosis; antivenoms; histopathological examination | ||||
|
Statistics Article View: 192 PDF Download: 95 |
||||
